10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
10x Genomics First Quarter 2024 Earnings: In Line With Expectations
Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies
UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating
10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09
10x Genomics Cut to Hold From Buy by TD Cowen
10x Genomics Cut to Hold From Buy by TD Cowen
TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.
TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.
10x Genomics, Inc. (NASDAQ:TXG) Q1 2024 Earnings Call Transcript
10x Genomics Is Maintained at Buy by Stifel
10x Genomics Is Maintained at Buy by Stifel
10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel
10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel
Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53
Stifel analyst Daniel Arias maintains 10x Genomics with a Buy and lowers the price target from $63 to $53.
10x Genomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 105.43% Stifel $63 → $53 Maintains Buy 04/29/2024 93.8% Canaccord Genuity $65 → $50 Maintains B
Earnings Call Summary | 10x Genomics(TXG.US) Q1 2024 Earnings Conference
The following is a summary of the 10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript:Financial Performance:10x Genomics reported Q1 total revenue growth of 5% to $141 million.Consumption revenu
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
The European Unified Patent Court Clears Curio Seeker With Respect To Claim 1 Of EP 2697391 Asserted By 10x Genomics
The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ:TXG). The UPC has also ordered Curio B
10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a
10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.
10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.
10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches
Research Alert: CFRA Maintains Buy Opinion On Shares Of 10x Genomics, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We decrease our target price to $41 from
No Data